Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study

被引：0

作者：

Garcia-Campelo, M. R. ^{[1
]}

Domine, M. ^{[2
]}

Carpeno, J. De Castro ^{[3
]}

Vega, A. L. Moreno ^{[4
]}

Aix, S. Ponce ^{[5
]}

Arriola, E. ^{[6
]}

Carcereny, E. ^{[7
]}

Majem, M. ^{[8
]}

Vence, G. Huidobro ^{[9
]}

Gonzalez, E. Esteban ^{[10
]}

Pradera, J. Fuentes ^{[11
]}

Granados, A. L. O. Ortega ^{[12
]}

Morales, M. Guillot ^{[13
]}

Sureda, B. Massuti ^{[14
]}

Barragan, P. Lianes ^{[15
]}

Calderon, R. Alonso ^{[16
]}

Fajardo, C. A. ^{[17
]}

Crama, L. ^{[17
]}

Laborda, N. Lerones ^{[18
]}

Dols, M. Cobo ^{[19
]}

机构：

[1] CHUAC Complexo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[2] Fdn Jimenez Diaz, Med Oncol, Madrid, Spain

[3] Hosp Univ La Paz, Med Oncol Dept, Madrid, Spain

[4] Hosp Univ Virgen Rocio, Med Oncol Dept, Seville, Spain

[5] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[6] Hosp Mar, Med Oncol Dept, Parc Salut Mar, Barcelona, Spain

[7] Hosp Badalona Germans Trias & Pujol, Med Oncol Dept, ICO Inst Catala Oncol Badalona, Barcelona, Spain

[8] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain

[9] CHUVI Complejo Hosp Univ Vigo, Med Oncol, Vigo, Spain

[10] Hosp Univ Cent Asturias, Med Oncol Dept, Oviedo, Spain

[11] Hosp Univ Virgen Valme, Med Oncol Dept, Seville, Spain

[12] Hosp Univ Jaen, Med Oncol Dept, Jaen, Spain

[13] Hosp Univ Son Espases, Oncol, Palma de Mallorca, Spain

[14] Hosp Gen Univ Alicante, Med Oncol Dept, Alicante, Spain

[15] Hosp Mataro, Dept Med Oncol, Consorcio Sanitario Maresme, Barcelona, Spain

[16] Hosp San Pedro de Alcantara, Med Oncol, Caceres, Spain

[17] Roche Farma SA, Med Affairs Dept, Madrid, Spain

[18] Roche Farma SA, Clin Operat, Madrid, Spain

[19] Hosp Reg Univ Malaga Carlos Haya, Med Oncol Dept, Malaga, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1226

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1995P

引用

页码：S1064 / S1065

页数：2

共 50 条

[1] Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study
Garcia-Campelo, R.
Domine Gomez, M.
de Castro, J.
Moreno Vega, A.
Ponce Aix, S.
Arriola, E.
Carcereny, E.
Majem, M.
Huidobro Vence, G.
Esteban Gonzalez, E.
Fuentes Pradera, J.
Ortega Granados, A. L.
Guillot Morales, M.
Massuti Sureda, B.
Fernandez Nunez, N.
Provencio, M.
Gonzalez-Mancha, N.
Fajardo, C. A.
Lerones, N.
Cobo Dols, M.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S211 - S212
[2] IMfirst; Phase IIIB Safety Study of Atezolizumab Plus Chemotherapy in a Real World Population of Untreated ES-SCLC
Garcia Campelo, R.
De Castro Carpeno, J.
Cobo Dols, M.
Moreno Vega, A.
Majem Tarruella, M.
Arriola Aperribay, E.
Crama, L.
Ruiz Gracia, P.
Domine Gomez, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S500 - S501
[3] Predictors of long-term response and survival in patients with extensive stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus chemotherapy in a real-world setting (IFCT-1905 CLINATEZO)
Falchero, L.
Amrane, K.
Godbert, B.
Leterre, B.
Madelaine, J.
Fournel, P.
Mascaux, C.
Raimbourg, J.
Schneider, S.
Swalduz, A.
Veillon, R.
Langlais, A.
Missy, P.
Morin, F.
Westeel, V.
Girard, N.
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03)
[4] Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study
Garcia-Campelo, R.
Domine Gomez, M.
de Castro, J.
Moreno Vega, A.
Ponce Aix, S.
Arriola, E.
Carcereny, E.
Majem Tarruella, M.
Huidobro Vence, G.
Esteban Gonzalez, E.
Fuentes Pradera, J.
Ortega Granados, A. L.
Guillot Morales, M.
Massuti Sureda, B.
Vila, L.
Blasco Cordellat, A.
Fajardo, C. A.
Crama, L.
Lerones, N.
Cobo Dols, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S372 - S372
[5] Efficacy and Safety Analysis of Atezolizumab Continuation Beyond Progression in Extensive Small Cell Lung Cancer(ES-SCLC)
Peng, Y.
Shi, W.
Bao, X.
Xiong, J.
Yang, Z.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S665 - S666
[6] Patterns of Disease Progression after Carboplatin/Etoposide plus Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Higgins, K. A.
Curran, W. J., Jr.
Liu, S. V.
Yu, W.
Brockman, M.
Johnson, A.
Bara, I.
Bradley, J. D.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (05): : 1398 - 1398
[7] Prognostic Laboratory Parameters in Imfirst: Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
de Castro, J.
Cobo Dols, M.
Domine Gomez, M.
Moreno Vega, A.
Ponce Aix, S.
Arriola, E.
Carcereny, E.
Majem, M.
Huidobro Vence, G.
Esteban Gonzalez, E.
Fuentes Pradera, J.
Ortega Granados, A. L.
Guillot Morales, M.
Massuti Sureda, B.
Fernandez Nunez, N.
Provencio, M.
Gonzalez-Mancha, N.
Fajardo, C. A.
Lerones, N.
Garcia Campelo, R.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S662 - S663
[8] COST OF IMMUNOTHERAPY TO TREAT EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Bilir, S. P.
Ogale, S.
VALUE IN HEALTH, 2020, 23 : S36 - S36
[9] Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
Daniel, D.
Kuchava, V.
Bondarenko, I.
Ivashchuk, O.
Spigel, D.
Dasgupta, A.
Reddy, S.
Melkadze, T.
Jaal, J.
Kudaba, I.
Hart, L.
Matitashvili, A.
Koynov, K. D.
Yang, Z.
Wolfe, S. G.
Malik, R.
Morris, S. R.
Antal, J. M.
Goldschmidt, J.
ANNALS OF ONCOLOGY, 2019, 30 : 713 - 713
[10] Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Goldman, J.
Cummings, A.
Mendenhall, M.
Velez, M. A.
Babu, S.
Johnson, T.
Alcantar, J.
Dakhil, S.
Kanamori, D.
Lawler, W.
Anand, S.
Chauv, J.
Garon, E.
Slamon, D.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S32 - S32

← 1 2 3 4 5 →